期刊文献+

肝硬化腹水与血钠关系研究 被引量:5

Study on the relationship between liver cirrhosis ascites and plasma sodium
原文传递
导出
摘要 目的比较补钠与限钠对肝硬化腹水消退和预后的影响,研究肝硬化腹水与血钠关系。方法119例肝硬化患者随机分为补钠组60例、限钠组59例。补钠组低盐饮食,静脉补氯化钠(3—5)g/d;限钠组低盐饮食。治疗前、后6d和12d检测血和尿中钠、氯,观察尿量、腹水消退和临床转归情况。结果补钠组治疗后12d血钠(139.06±7.01)mmol/L、血氯(105.76±5.46)mmol/L与同组治疗前和治疗后6d比较(P〈0.05),与限钠组治疗后12d比较(P〈0.01),尿钠(269.04±61.23)mmol/L、尿氯(249.21±38.98)mmol/L、尿量(2445.83±609.09)ml/d,与同组治疗前和治疗后6d比较(P〈0.01);与限钠组治疗后12d比较(P〈0.05),补钠组腹水消退时间、肝性脑病、肝肾综合征的发生率、病死率均低于限钠组。结论肝硬化腹水适当补钠有利于腹水消退,可以改善患者的预后。 Objective To compare sodium supplement and sodium restriction to the effect of the extinction and prognosis of liver cirrhosis ascites, and research the relationship between live cirrhosis ascites and plasma sodium. Methods 119 liver cirrhosis patients were randomly divided into 2 groups :60 cases of sodium supplement and 59 cases of sodium restriction. 60 cases of sodium supplement was kept low-salt diet and intravenous sodium chloride supplement (3- 5 g/d) ,59 cases of sodium restriction was only kept low-salt dict. Plasma sodium, plasma chloride, urine sodium,urine sodium chloride were detected before treatment, and 6 days, 10 days after treatment respectively. And the urine quantity,extinction of ascites and prognosis were compared. Results There were significant differences on the increase of plasma sodium, plasma chloride, urine sodium, urine chloride and urine quantity after treatment in two groups. Extinction time of ascites was shorter in group of sodium supplement. The morbidity and fatality rate of hepatic enccphalopathy, and hepatorenal syndrome in the group of sodium supplement were lower than that in the group of sodium restriction. Conclusion Sodium supplement should be adapted when using diuretic agent to help the extinction of ascites, and to improve recovery.
出处 《中国基层医药》 CAS 2010年第17期2348-2349,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 肝硬化 电解质 腹水 Liver cirrhosis ascites Sodium supplement Extinction of ascites
  • 相关文献

参考文献6

二级参考文献21

  • 1丘肇钢.肝硬化腹水的低钠血症[J].临床肝胆病杂志,1994,10(3):165-166. 被引量:35
  • 2Wong F, Blendis L. New challenge of hepatorenal syndrome : Prevention and treatment [ J ]. Hepatology ,2001,34 ( 6 ) : 1242 - 1251.
  • 3Arroyo V, Jimenez W. Complications of cirrhosis. Ⅱ Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.J Hepatol, 2000, 32 (1): 157-170.
  • 4Wong F, Blendis L. The pathophysiologic basis for the treatment of cirrhotic ascites: Clin Liver Dis, 2001, 5 (3) : 819 -832.
  • 5Martin PY, Sehrier RW. Pathogenesis of water and sodium retention in cirrhosis. Kidenty Int Suppl, 1997, 59 (6): 43-49.
  • 6李绍白.肝硬化难治性腹水的治疗.见:徐克成.江石湖,主编.消化病现代治疗.上海:上海科技出版社,2001:432-442.
  • 7崔俊,杨冬华.肝硬化低钠血症的治疗.见:杨冬华.陈曼湖,主编.消化系疾病治疗学.北京:人民卫生出版社,2005:670-672.
  • 8陈燕,段洪云,李先,曹维雄.肝硬化患者39例并发低钠血症临床分析[J].疑难病杂志,2007,6(11):681-682. 被引量:5
  • 9Decaux G.Difference is solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985[].Journal of Laboratory and Clinical Medicine.2001
  • 10Gadano A,Moreau R,Pessione F,et al.Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis[].Journal of Hepatology.2000

共引文献115

同被引文献60

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部